CervoMed (CRVO) 10-Q 10 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 08, 2021
Document Information [Line Items]
Entity Central Index Key	0001053691
Entity Registrant Name	Diffusion Pharmaceuticals Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	000-24477
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	30-0645032
Entity Address, Address Line One	300 East Main Street, Suite 201
Entity Address, City or Town	Charlottesville
Entity Address, State or Province	VA
Entity Address, Postal Zip Code	22902
City Area Code	434
Local Phone Number	220-0718
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	DFFN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		101,920,329

Consolidated Balance Sheets (Cu

Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 40,335,045	$ 18,515,595
Prepaid expenses, deposits and other current assets	380,097	260,825
Total current assets	40,715,142	18,776,420
Property and equipment, net	81,896	149,198
Intangible asset	0	8,639,000
Right of use asset	67,886	149,162
Other assets	15,579	15,771
Total assets	40,880,503	27,729,551
Current liabilities:
Accounts payable	678,036	545,844
Accrued expenses and other current liabilities	2,002,981	1,776,470
Current operating lease liability	67,886	113,469
Total current liabilities	2,748,903	2,435,783
Deferred income taxes	0	443,893
Noncurrent operating lease liability	0	35,693
Total liabilities	2,748,903	2,915,369
Commitments and Contingencies (Note 7)
Stockholders’ Equity:
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 101,903,979 and 64,015,441 shares issued and outstanding at September 30, 2021 and December 31, 2020, respectively	101,904	64,016
Additional paid-in capital	164,560,366	130,659,550
Accumulated deficit	(126,530,670)	(105,909,384)
Total stockholders' equity	38,131,600	24,814,182
Total liabilities and stockholders' equity	$ 40,880,503	$ 27,729,551

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, shares issued (in shares)	101,903,979	64,015,441
Common stock, shares outstanding (in shares)	101,903,979	64,015,441

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 2,105,815	$ 3,137,553	$ 6,994,866	$ 6,845,203
Intangible asset impairment charge	8,639,000	0	8,639,000	0
General and administrative	1,930,082	2,112,375	5,510,365	4,964,440
Depreciation	19,100	24,192	67,302	78,233
Loss from operations	12,693,997	5,274,120	21,211,533	11,887,876
Other income:
Interest income	(50,710)	(29,233)	(146,354)	(89,246)
Loss from operations before income tax benefit	(12,643,287)	(5,244,887)	(21,065,179)	(11,798,630)
Income tax benefit	443,893	805,676	443,893	1,675,381
Net loss	(12,199,394)	(4,439,211)	(20,621,286)	(10,123,249)
Deemed dividend arising from warrant exchange	0	0	0	(1,950,378)
Net loss attributable to common stockholders	$ (12,199,394)	$ (4,439,211)	$ (20,621,286)	$ (12,073,627)
Per share information:
Net loss per share of common stock, basic and diluted (in dollars per share)	$ (0.12)	$ (0.07)	$ (0.22)	$ (0.24)
Weighted average shares outstanding, basic and diluted (in dollars per share)	$ 101,903,979	$ 64,011,342	$ 98,810,420	$ 50,216,239

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	33,480,365
Balance at Dec. 31, 2019	$ 33,481	$ 111,824,859	$ (91,724,078)	$ 20,134,262
Issuance of common stock upon exercise of warrants (in shares)	19,106,504
Issuance of common stock upon exercise of warrants	$ 19,106	7,768,370	0	7,787,476
Stock-based compensation expense	0	584,297	0	584,297
Net loss	$ 0	0	(10,123,249)	(10,123,249)
Sale of common stock and warrants, net of issuance costs (in shares)	11,428,572
Sale of common stock and warrants, net of issuance costs	$ 11,429	10,330,202	0	10,341,631
Balance (in shares) at Sep. 30, 2020	64,015,441
Balance at Sep. 30, 2020	$ 64,016	130,507,728	(101,847,327)	28,724,417
Balance (in shares) at Jun. 30, 2020	63,998,298
Balance at Jun. 30, 2020	$ 63,999	130,220,772	(97,408,116)	32,876,655
Issuance of common stock upon exercise of warrants (in shares)	17,143
Issuance of common stock upon exercise of warrants	$ 17	7,483	0	7,500
Stock-based compensation expense	0	279,473	0	279,473
Net loss	$ 0	0	(4,439,211)	(4,439,211)
Balance (in shares) at Sep. 30, 2020	64,015,441
Balance at Sep. 30, 2020	$ 64,016	130,507,728	(101,847,327)	28,724,417
Balance (in shares) at Dec. 31, 2020	64,015,441
Balance at Dec. 31, 2020	$ 64,016	130,659,550	(105,909,384)	24,814,182
Issuance of common stock upon exercise of warrants (in shares)	4,230,000
Issuance of common stock upon exercise of warrants	$ 4,230	2,197,220	0	2,201,450
Stock-based compensation expense	0	642,952	0	642,952
Net loss	$ 0	0	(20,621,286)	(20,621,286)
Sale of common stock and warrants, net of issuance costs (in shares)	33,658,538
Sale of common stock and warrants, net of issuance costs	$ 33,658	31,060,644	0	31,094,302
Balance (in shares) at Sep. 30, 2021	101,903,979
Balance at Sep. 30, 2021	$ 101,904	164,560,366	(126,530,670)	38,131,600
Balance (in shares) at Jun. 30, 2021	101,903,979
Balance at Jun. 30, 2021	$ 101,904	164,395,974	(114,331,276)	50,166,602
Stock-based compensation expense	0	164,392	0	164,392
Net loss	$ 0	0	(12,199,394)	(12,199,394)
Balance (in shares) at Sep. 30, 2021	101,903,979
Balance at Sep. 30, 2021	$ 101,904	$ 164,560,366	$ (126,530,670)	$ 38,131,600

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Operating activities:
Net loss	$ (20,621,286)	$ (10,123,249)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	67,302	78,233
Stock-based compensation expense	642,952	584,297
Deferred income taxes	(443,893)	(1,675,381)
Intangible asset impairment charge	8,639,000	0
Changes in operating assets and liabilities:
Prepaid expenses, deposits and other assets	(119,080)	(224,224)
Accounts payable, accrued expenses and other liabilities	358,703	1,202,283
Net cash used in operating activities	(11,476,302)	(10,158,041)
Cash flows provided by financing activities:
Proceeds from the sale of common stock and warrants, net of issuance costs	31,094,302	10,827,100
Proceeds from the exercise of common stock warrants	2,201,450	8,046,103
Payment of financing costs	0	(982,328)
Net cash provided by financing activities	33,295,752	17,890,875
Net increase in cash and cash equivalents	21,819,450	7,732,834
Cash and cash equivalents at beginning of period	18,515,595	14,177,349
Cash and cash equivalents at end of period	$ 40,335,045	$ 21,910,183

Note 1 - Organization and Descr

Note 1 - Organization and Description of Business	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Nature of Operations [Text Block]	1. Organization and Description of Business Diffusion Pharmaceuticals Inc., a Delaware corporation, is a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed most. The Company’s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and difficult-to-treat conditions.

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Liquidity Disclosure [Text Block]	2. Liquidity The Company has not No The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with third not may third may not Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company’s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company’s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company’s financial condition and future operations. The Company expects that its existing cash and cash equivalents as of September 30, 2021 2023.

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	3. Basis of Presentation and Summary of Significant Accounting Policies The Summary of Significant Accounting Policies included in the Company's Annual Report for the year ended December 31, 2020 not Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10 10 X September 30, 2021, three nine September 30, 2021 2020 nine September 30, 2021 2020. nine September 30, 2021 not may December 31, 2021. not December 31, 2020 10 March 16, 2021. Use of Estimates The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. The COVID- 19 no three nine September 30, 2021. 19 may 19, 19, may 19, Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments. Intangible Asset In the third 2021, no 529 529 529 third 2021. Net Loss Per Common Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive as of the dates indicated below: As of September 30, 2021 2020 Common stock warrants 6,499,469 9,100,112 Stock options 3,799,815 2,040,204 Unvested restricted stock awards 291,800 153,000 10,591,084 11,293,316 Recently Adopted Accounting Pronouncements In December 2019, No. 2019 12, 740 Simplifying the Accounting for Income Taxes December 15, 2020 No. 2019 12 first 2021 not

Note 4 - Accrued Expenses and O

Note 4 - Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	4. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following as of the dates indicated below: September 30, 2021 December 31, 2020 Accrued payroll and payroll related expenses 773,917 653,899 Accrued professional fees 59,126 31,809 Accrued clinical studies expenses 1,081,453 1,055,398 Other accrued expenses 88,485 35,364 Total $ 2,002,981 $ 1,776,470

Note 5 - Stockholders' Equity a

Note 5 - Stockholders' Equity and Common Stock Warrants	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	5. Stockholders' Equity and Common Stock Warrants February 2021 In February 2021, February 2021 February 2021 February 2021 five Common Stock Warrants As of September 30, 2021, Outstanding Range of exercise price per share Expiration dates Common stock warrants issued in 2017 related to Series A convertible preferred stock offering 903,870 $33.30 March 2022 Common stock warrants issued in 2018 related to the January 2018 Offering 1,181,421 $12.00 - $15.00 January 2023 Common stock warrants issued related to the May 2019 Offering 1,382,913 $5.00 - $6.11875 May and December 2024 Common stock warrants issued related to the November 2019 Offering 213,570 $0.35 November 2024 Common stock warrants issued related to the December 2019 Offering 313,339 $0.4335 - $0.6981 December 2024 and June 2025 Common stock warrants issued related to the May 2020 Offering 571,429 $1.31 May 2025 Common stock warrants issued related to May 2020 Investor Warrant Exercise 250,000 $0.5938 November 2025 Common stock warrants issued related to the February 2021 Offering 1,682,927 $1.28 February 2026 6,499,469 During the nine September 30, 2021,

Note 6 - Stock-based Compensati

Note 6 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	6. Stock-Based Compensation 2015 The 2015 January 1 December 31, January 1, 2021, may 2015 September 30, 2021, 2015 The Company recorded stock-based compensation expense in the following expense categories of its unaudited interim consolidated statements of operations for the periods indicated: Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 18,811 $ 19,838 $ 111,378 $ 136,236 General and administrative 145,581 259,635 531,574 448,061 Total stock-based compensation expense $ 164,392 $ 279,473 $ 642,952 $ 584,297 The following table summarizes the activity related to all stock option grants for the nine September 30, 2021: Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Aggregate intrinsic value Balance at January 1, 2021 2,240,204 $ 8.28 Granted 1,732,515 0.91 Forfeited (172,904 ) 1.76 Outstanding at September 30, 2021 3,799,815 $ 5.22 8.79 $ 33,791 Exercisable at September 30, 2021 1,839,079 $ 9.85 8.17 $ 30,113 Vested and expected to vest at September 30, 2021 3,542,971 $ 5.51 8.74 $ 33,791 The weighted average grant date fair value of stock option awards granted during the nine September 30, 2021 three September 30, 2021 2020 nine September 30, 2021 2020 No September 30, 2021, nine September 30, 2021, nine September 30, 2021, not September 30, 2021, no Options granted were valued using the Black-Scholes option-pricing model and the weighted average assumptions used to value the options granted during the nine September 30, 2021 2020 2021 2020 Expected term (in years) 10 7.75 Risk-free interest rate 1.5 % 0.9 % Expected volatility 123.8 % 119.7 % Dividend yield — % — % Restricted Stock Unit Awards The Company issues restricted stocks ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning 18 months after the respective grant date. The fair value of an RSU is equal to the fair market value price of the Company’s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period. The following table summarizes activity related to RSU stock-based payment awards: Number of shares Weighted-average grant date fair value Unvested balance at January 1, 2021 153,000 $ 0.65 Granted 138,800 $ 0.72 Unvested balance at September 30, 2021 291,800 $ 0.69 The Company recognized approximately $16,000 and $4,000 in expense related to these awards during the three September 30, 2021 2020, nine September 30, 2021 2020, September 30, 2021,

Note 7 - Commitments and Contin

Note 7 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	7. Commitments and Contingencies Office Space Rental The Company has a non-cancelable operating lease for office and laboratory space in Charlottesville, Virginia, which began in April 2017, September 30, 2021, 842 second 2022 five not September 30, 2021. two nine September 30, 2021. 842 not Rent expense related to the Company's operating leases for the three September 30, 2021 2020 nine September 30, 2021 2020 September 30, 2021 Rental Commitments 2021 $ 29,801 2022 39,735 Total 69,536 Less: imputed interest (1,650 ) $ 67,886 Research and Development Arrangements In the course of normal business operations, the Company enters into agreements with universities and CROs to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which may Defined Contribution Retirement Plan The Company has established a 401 may 401 401 three September 30, 2021 2020, nine September 30, 2021 2020, Legal Proceedings On August 7, 2014, No. BC553996 December 30, 2014, April 1, 2015, April 14, 2015, January 8, 2016, November 19, 2018 not November 2020 19 November 2018 October 22, 2021, not February 23, 2022 The Company believes the claims in this matter are without merit and intends to defend itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may

Note 8 - Subsequent Events

Note 8 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	8. Subsequent Events Lease Termination On November 8, 2021, April 30, 2022 September 30, 2021, one In lieu of the fixed office and laboratory space previously available to us under the Carlton Lease, we have recently entered into short term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania. Nasdaq Bid Price Deficiency Notice As previously disclosed, on May 6, 2021, 5550 2 not $1.00 30 5810 3 180 November 2, 2021, On November 3, 2021, not November 2, 2021, 5810 3 180 May 2, 2022, $1.00 10 The Notice has no

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying unaudited interim consolidated financial statements of the Company have been prepared in accordance with GAAP for interim financial information as found in the ASC and ASUs of the FASB, and with the instructions to Form 10 10 X September 30, 2021, three nine September 30, 2021 2020 nine September 30, 2021 2020. nine September 30, 2021 not may December 31, 2021. not December 31, 2020 10 March 16, 2021.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of unaudited interim consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date the financial statements and reported amounts of expense during the reporting period. The COVID- 19 no three nine September 30, 2021. 19 may 19, 19, may 19,
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The carrying amounts of the Company’s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.
Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Asset In the third 2021, no 529 529 529 third 2021.
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Common Share Basic net loss per share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive as of the dates indicated below: As of September 30, 2021 2020 Common stock warrants 6,499,469 9,100,112 Stock options 3,799,815 2,040,204 Unvested restricted stock awards 291,800 153,000 10,591,084 11,293,316
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In December 2019, No. 2019 12, 740 Simplifying the Accounting for Income Taxes December 15, 2020 No. 2019 12 first 2021 not

Note 3 - Basis of Presentatio_2

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	As of September 30, 2021 2020 Common stock warrants 6,499,469 9,100,112 Stock options 3,799,815 2,040,204 Unvested restricted stock awards 291,800 153,000 10,591,084 11,293,316

Note 4 - Accrued Expenses and_2

Note 4 - Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Other Current Liabilities [Table Text Block]	September 30, 2021 December 31, 2020 Accrued payroll and payroll related expenses 773,917 653,899 Accrued professional fees 59,126 31,809 Accrued clinical studies expenses 1,081,453 1,055,398 Other accrued expenses 88,485 35,364 Total $ 2,002,981 $ 1,776,470

Note 5 - Stockholders' Equity_2

Note 5 - Stockholders' Equity and Common Stock Warrants (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Outstanding Range of exercise price per share Expiration dates Common stock warrants issued in 2017 related to Series A convertible preferred stock offering 903,870 $33.30 March 2022 Common stock warrants issued in 2018 related to the January 2018 Offering 1,181,421 $12.00 - $15.00 January 2023 Common stock warrants issued related to the May 2019 Offering 1,382,913 $5.00 - $6.11875 May and December 2024 Common stock warrants issued related to the November 2019 Offering 213,570 $0.35 November 2024 Common stock warrants issued related to the December 2019 Offering 313,339 $0.4335 - $0.6981 December 2024 and June 2025 Common stock warrants issued related to the May 2020 Offering 571,429 $1.31 May 2025 Common stock warrants issued related to May 2020 Investor Warrant Exercise 250,000 $0.5938 November 2025 Common stock warrants issued related to the February 2021 Offering 1,682,927 $1.28 February 2026 6,499,469

Note 6 - Stock-based Compensa_2

Note 6 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Research and development $ 18,811 $ 19,838 $ 111,378 $ 136,236 General and administrative 145,581 259,635 531,574 448,061 Total stock-based compensation expense $ 164,392 $ 279,473 $ 642,952 $ 584,297
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Options Weighted average exercise price per share Weighted average remaining contractual life (in years) Aggregate intrinsic value Balance at January 1, 2021 2,240,204 $ 8.28 Granted 1,732,515 0.91 Forfeited (172,904 ) 1.76 Outstanding at September 30, 2021 3,799,815 $ 5.22 8.79 $ 33,791 Exercisable at September 30, 2021 1,839,079 $ 9.85 8.17 $ 30,113 Vested and expected to vest at September 30, 2021 3,542,971 $ 5.51 8.74 $ 33,791
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2021 2020 Expected term (in years) 10 7.75 Risk-free interest rate 1.5 % 0.9 % Expected volatility 123.8 % 119.7 % Dividend yield — % — %
Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]	Number of shares Weighted-average grant date fair value Unvested balance at January 1, 2021 153,000 $ 0.65 Granted 138,800 $ 0.72 Unvested balance at September 30, 2021 291,800 $ 0.69

Note 7 - Commitments and Cont_2

Note 7 - Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Rental Commitments 2021 $ 29,801 2022 39,735 Total 69,536 Less: imputed interest (1,650 ) $ 67,886

Note 3 - Basis of Presentatio_3

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)	$ 8,639,000	$ 0	$ 8,639,000	$ 0
Income Tax Expense (Benefit), Total	$ (443,893)	$ (805,676)	$ (443,893)	$ (1,675,381)

Note 3 - Basis of Presentatio_4

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Anti-dilutive securities (in shares)	10,591,084	11,293,316
Warrant [Member]
Anti-dilutive securities (in shares)	6,499,469	9,100,112
Share-based Payment Arrangement, Option [Member]
Anti-dilutive securities (in shares)	3,799,815	2,040,204
Restricted Stock [Member]
Anti-dilutive securities (in shares)	291,800	153,000

Note 4 - Accrued Expenses and_3

Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Accrued payroll and payroll related expenses	$ 773,917	$ 653,899
Accrued professional fees	59,126	31,809
Accrued clinical studies expenses	1,081,453	1,055,398
Other accrued expenses	88,485	35,364
Total	$ 2,002,981	$ 1,776,470

Note 5 - Stockholders' Equity_3

Note 5 - Stockholders' Equity and Common Stock Warrants (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Feb. 28, 2021	Sep. 30, 2021	Sep. 30, 2020
Class of Warrant or Rights, Expired (in shares)		53,570
Class of Warrant or Right, Exercised During Period (in shares)		4,230,000
Proceeds from Warrant Exercises		$ 2,201,450	$ 8,046,103
Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,682,927
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 1.28125	$ 1.28
Warrants and Rights Outstanding, Term (Year)	5 years
Public Offering, Inclusive of Underwriter Shares [Member]
Stock Issued During Period, Shares, New Issues (in shares)	33,658,538
Shares Issued, Price Per Share (in dollars per share)	$ 1.025
Underwriter Option to Purchase Additional Shares, Term (Day)	30 days
Proceeds from Issuance of Common Stock	$ 31,100,000

Note 5 - Stockholders' Equity_4

Note 5 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares	Sep. 30, 2021	Feb. 28, 2021
Common stock warrants, outstanding (in shares)	6,499,469
Warrants Attached to Series A Convertible Preferred Stock [Member]
Common stock warrants, outstanding (in shares)	903,870
Range of exercise price (in dollars per share)	$ 33.30
Warrants Issued in Connection with the January 2018 Offering [Member]
Common stock warrants, outstanding (in shares)	1,181,421
Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member]
Range of exercise price (in dollars per share)	$ 12
Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member]
Range of exercise price (in dollars per share)	$ 15
Warrants Issued in Connection with May 2019 Public Offering [Member]
Common stock warrants, outstanding (in shares)	1,382,913
Warrants Issued in Connection with May 2019 Public Offering [Member] | Minimum [Member]
Range of exercise price (in dollars per share)	$ 5
Warrants Issued in Connection with May 2019 Public Offering [Member] | Maximum [Member]
Range of exercise price (in dollars per share)	$ 6.11875
Warrants Issued in Connection with the November 2019 Offering [Member]
Common stock warrants, outstanding (in shares)	213,570
Range of exercise price (in dollars per share)	$ 0.35
Warrants Issued in Connection with the December 2019 Offering [Member]
Common stock warrants, outstanding (in shares)	313,339
Warrants Issued in Connection with the December 2019 Offering [Member] | Minimum [Member]
Range of exercise price (in dollars per share)	$ 0.4335
Warrants Issued in Connection with the December 2019 Offering [Member] | Maximum [Member]
Range of exercise price (in dollars per share)	$ 0.6981
The May 2020 Offering Warrants [Member]
Common stock warrants, outstanding (in shares)	571,429
Range of exercise price (in dollars per share)	$ 1.31
The May 2020 Investor Warrant Exercise [Member]
Common stock warrants, outstanding (in shares)	250,000
Range of exercise price (in dollars per share)	$ 0.5938
Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]
Common stock warrants, outstanding (in shares)	1,682,927
Range of exercise price (in dollars per share)	$ 1.28	$ 1.28125

Note 6 - Stock-based Compensa_3

Note 6 - Stock-based Compensation (Details Textual) - USD ($)	Jan. 01, 2021	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)					$ 0.87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 300,000		$ 300,000	$ 600,000	$ 600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)			0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					1,732,515
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.91
Share-based Payment Arrangement, Expense		164,392		279,473	$ 642,952	584,297
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		1,200,000			$ 1,200,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					1 year 9 months 18 days
Share-based Payment Arrangement, Expense					$ 100,000
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)					385,267
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 1.11
Restricted Stock Units (RSUs) [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Month)					18 months
Restricted Stock [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)					2 years 4 months 6 days
Share-based Payment Arrangement, Expense		16,000		$ 4,000
Restricted Stock [Member] | Director [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 100,000			$ 100,000
Share-based Payment Arrangement, Expense					$ 27,000	$ 12,000
Equity Incentive Plan 2015 [Member]
Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis					4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	2,560,618
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		407,333			407,333

Note 6 - Stock-based Compensa_4

Note 6 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock-based compensation expense	$ 164,392	$ 279,473	$ 642,952	$ 584,297
Research and Development Expense [Member]
Stock-based compensation expense	18,811	19,838	111,378	136,236
General and Administrative Expense [Member]
Stock-based compensation expense	$ 145,581	$ 259,635	$ 531,574	$ 448,061

Note 6 - Stock-based Compensa_5

Note 6 - Stock-based Compensation - Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Options outstanding, number (in shares) | shares	2,240,204
Options outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 8.28
Granted (in shares) | shares	1,732,515
Granted, weighted-average exercise price (in dollars per share) | $ / shares	$ 0.91
Forfeited (in shares) | shares	(172,904)
Forfeited, weighted-average exercise price (in dollars per share) | $ / shares	$ 1.76
Options outstanding, number (in shares) | shares	3,799,815
Options outstanding, weighted-average exercise price (in dollars per share) | $ / shares	$ 5.22
Options outstanding, weighted-average remaining contractual life (Year)	8 years 9 months 14 days
Options outstanding, aggregate intrinsic value | $	$ 33,791
Exercisable (in shares) | shares	1,839,079
Exercisable, weighted-average exercise price (in dollars per share) | $ / shares	$ 9.85
Exercisable, weighted-average remaining contractual life (Year)	8 years 2 months 1 day
Exercisable, aggregate intrinsic value | $	$ 30,113
Vested and expected to vest (in shares) | shares	3,542,971
Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares	$ 5.51
Vested and expected to vest, weighted-average remaining contractual life (Year)	8 years 8 months 26 days
Vested and expected to vest, aggregate intrinsic value | $	$ 33,791

Note 6 - Stock-based Compensa_6

Note 6 - Stock-based Compensation - Fair Value Assumptions (Details) - Share-based Payment Arrangement, Option [Member]	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Expected term (Year)	10 years	7 years 9 months
Risk-free interest rate	1.50%	0.90%
Expected volatility	123.80%	119.70%
Dividend yield	0.00%	0.00%

Note 6 - Stock-based Compensa_7

Note 6 - Stock-based Compensation - RSU Stock-based Payment Awards (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Unvested, shares (in shares) | shares	153,000
Unvested, Weighted-average grant date fair value (in dollars per share) | $ / shares	$ 0.65
Granted, shares (in shares) | shares	138,800
GrantedWeighted-average grant date fair value (in dollars per share) | $ / shares	$ 0.72
Unvested, shares (in shares) | shares	291,800
Unvested, Weighted-average grant date fair value (in dollars per share) | $ / shares	$ 0.69

Note 7 - Commitments and Cont_3

Note 7 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Lessee, Operating Lease, Remaining Lease Term (Year)	7 months 6 days		7 months 6 days
Lessee, Operating Lease, Discount Rate	10.00%		10.00%
Lessee, Operating Lease, Renewal Term (Year)	5 years		5 years
Operating Lease, Expense	$ 48,000	$ 30,000	$ 100,000	$ 91,000
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent			90.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay			4.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 29,000	$ 11,000	$ 60,000	$ 42,000

Note 7 - Commitments and Cont_4

Note 7 - Commitments and Contingencies - Future Minimum Rental Payments (Details)	Sep. 30, 2021USD ($)
2021	$ 29,801
2022	39,735
Total	69,536
Less: imputed interest	(1,650)
Operating Lease, Liability	$ 67,886

Note 8 - Subsequent Events (Det

Note 8 - Subsequent Events (Details Textual) - USD ($)	Nov. 08, 2021	Sep. 30, 2021
Lessee, Operating Lease, Liability, to be Paid, Total		$ 69,536
Subsequent Event [Member] | Carlton Landlord [Member]
Operating Lease, Payments	$ 14,000